Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
DVD0E9
|
|||
| Drug Name |
Quaratusugene ozeplasmid
|
|||
| Synonyms |
GPX-001; CNVN 202
Click to Show/Hide
|
|||
| Drug Type |
Gene therapy
|
|||
| Indication | Non-small-cell lung cancer [ICD-11: 2C25.Y; ICD-9: 162] | Phase 1/2 | [1] | |
| Company |
Genprex
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Tumor suppressor candidate 2 (TUSC2) | Target Info | . | [2] |
| WikiPathways | miR-targeted genes in muscle cell - TarBase | |||
| miR-targeted genes in lymphocytes - TarBase | ||||
| miR-targeted genes in leukocytes - TarBase | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT04486833) TUSC2-nanoparticles (GPX-001) and Osimertinib in Patients With Stage IV Lung Cancer Who Progressed on Osimertinib Alone. U.S. National Institutes of Health. | |||
| REF 2 | Clinical pipeline report, company report or official report of Genprex. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.